Caval valve implantation (CAVI) for severe tricuspid regurgitation

Scott A, Kern J, Vreugdenburg T
Record ID 32018013183
English
Authors' objectives: Tricuspid regurgitation (TR) occurs when the tricuspid valve does not close properly, allowing blood to flow backward into the right atrium and reducing the amount of blood that flows to the rest of the body. Treatment options for TR include medical therapy, open-heart surgery or transcatheter interventions. Caval valve implantation, or "CAVI" in short, is an emerging transcatheter intervention for patients with TR who are at high surgical risk.
Authors' results and conclusions: A total of five studies, including one RCT (n=28 patients) and four case series (n=105 patients), were included to assess the efficacy and safety of CAVI. The studies suggest a similar (marginal) efficacy of CAVI compared to optimal medical therapy, but with an additional risk of life-threatening procedure-related adverse events.
Details
Project Status: Completed
URL for project: https://aihta.at/page/bewertung-medizinischer-einzelleistungen-mel-2024/en
Year Published: 2024
URL for published report: https://eprints.aihta.at/1525/1/DSD_139.pdf
URL for additional information: https://eprints.aihta.at/1525/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Tricuspid Valve
  • Tricuspid Valve Insufficiency
  • Heart Valve Prosthesis Implantation
  • Heart Valve Prosthesis
  • Heart Valve Diseases
Keywords
  • Tricuspid insufficiency
  • percutaneous repair
  • caval valve implantation
  • transcatheter intervention
Contact
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name: office@aihta.at
Contact Email: office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.